Literature DB >> 15695494

Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease.

Clifford C Taggart1, Catherine M Greene, Tomas P Carroll, Shane J O'Neill, Noel G McElvaney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15695494     DOI： 10.1164/rccm.200407-881PP

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  41 in total

Review 1.  Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?

Authors:  Charles N Serhan
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

2.  Serine protease activity contributes to control of Mycobacterium tuberculosis in hypoxic lung granulomas in mice.

Authors:  Stephen T Reece; Christoph Loddenkemper; David J Askew; Ulrike Zedler; Sandra Schommer-Leitner; Maik Stein; Fayaz Ahmad Mir; Anca Dorhoi; Hans-Joachim Mollenkopf; Gary A Silverman; Stefan H E Kaufmann
Journal:  J Clin Invest       Date:  2010-08-02       Impact factor: 14.808

3.  Expression levels of matrix metalloproteinase (MMP)-9 and its specific inhibitor TIMP-1, in septic and aseptic arthritis of the knee.

Authors:  Vasileios Christos Fotopoulos; Athina Tzinia; Matthew Tzurbakis; Vasiliki Kalfakakou; Stamatina Levidiotou-Stefanou; Anastasios Georgoulis
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2011-09-24       Impact factor: 4.342

4.  Z α-1 antitrypsin deficiency and the endoplasmic reticulum stress response.

Authors:  Catherine M Greene; Noel G McElvaney
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-10-06

5.  A secretory leukocyte protease inhibitor variant with improved activity against lung infection.

Authors:  N Camper; A M A Glasgow; M Osbourn; D J Quinn; D M Small; D T McLean; F T Lundy; J S Elborn; P McNally; R J Ingram; S Weldon; C C Taggart
Journal:  Mucosal Immunol       Date:  2015-09-16       Impact factor: 7.313

6.  Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.

Authors:  Sinéad Weldon; Paul McNally; Noel G McElvaney; J Stuart Elborn; Danny F McAuley; Julien Wartelle; Abderrazzaq Belaaouaj; Rodney L Levine; Clifford C Taggart
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

7.  Molecular principles for heparin oligosaccharide-based inhibition of neutrophil elastase in cystic fibrosis.

Authors:  Apparao B Kummarapurugu; Daniel K Afosah; Nehru Viji Sankaranarayanan; Rahaman Navaz Gangji; Shuo Zheng; Thomas Kennedy; Bruce K Rubin; Judith A Voynow; Umesh R Desai
Journal:  J Biol Chem       Date:  2018-06-14       Impact factor: 5.157

8.  Catalytic activity and inhibition of wegener antigen proteinase 3 on the cell surface of human polymorphonuclear neutrophils.

Authors:  Brice Korkmaz; Jérôme Jaillet; Marie-Lise Jourdan; Alexandre Gauthier; Francis Gauthier; Sylvie Attucci
Journal:  J Biol Chem       Date:  2009-05-15       Impact factor: 5.157

9.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30

10.  Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides--comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea.

Authors:  Inken Groth; Niels Grünewald; Susanne Alban
Journal:  Glycobiology       Date:  2008-12-23       Impact factor: 4.313
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.